• Home
  • Our Mission
  • Our Science
  • Team
  • Careers
  • News & Publications
  • Contact
Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

by dividef | May 17, 2022 | Press Release

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting Read...
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

by dividef | May 10, 2022 | Press Release

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board Read...
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

by dividef | May 5, 2022 | Press Release

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis Read...

Recent Posts

  • Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
  • Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
  • Genascence Appoints Jeymi Tambiah as Chief Medical Officer
  • Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)
  • Genascence to Present at Biotech Showcase 2024

Recent Comments

    Archives

    • May 2025
    • January 2025
    • October 2024
    • January 2024
    • December 2023
    • October 2023
    • February 2023
    • May 2022

    Categories

    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact | Privacy Policy

    ©2022. Genascence. All Rights Reserved. Site by GOODLAB